Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy

Sep 24, 2025Current drug metabolism

Addressing Metabolism Problems in Alzheimer's Disease as a Possible Treatment Approach

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

Impaired glucose metabolism and mitochondrial dysfunction are frequently observed in Alzheimer's disease (AD) brains.

Metabolic dysfunction may exacerbate neurodegeneration and cognitive deficits in AD.
Key disruptions include insulin resistance, reduced cerebral glucose utilization, and mitochondrial inefficiency.
Therapeutic approaches targeting metabolic pathways, such as insulin sensitizers and ketogenic diets, have shown promise in early studies.
Modulating lipid metabolism, like enhancing cholesterol efflux or reducing neurotoxic ceramides, could offer potential interventions.
Neuroinflammation and oxidative stress may mediate metabolic dysfunction in AD, highlighting the need for multifaceted treatment strategies.
Precision medicine may enable tailored interventions based on individual metabolic profiles to enhance treatment efficacy.

AI simplified

Alzheimer's disease (AD), the most common form of dementia, is characterized by progressive cognitive decline and neuropathological hallmarks, including amyloid-beta plaques and tau tangles. Emerging evidence implicates metabolic dysfunction as a critical contributor to the pathogenesis and pro-gression of AD. Impaired glucose metabolism, mitochondrial dysfunction, oxidative stress, and lipid dysregulation are frequently observed in AD brains, suggesting that metabolic dysfunction may exacerbate neurodegeneration and cognitive deficits. This review explores the therapeutic potential of targeting met-abolic pathways to mitigate AD pathology. Key metabolic disruptions, including insulin resistance, re-duced cerebral glucose utilization, and mitochondrial inefficiency, are closely linked to neuronal energy deficits and synaptic dysfunction. Therapeutic approaches, such as insulin sensitizers, ketogenic diets, and mitochondrial-targeted antioxidants, have shown promise in preclinical and early clinical studies. Addi-tionally, strategies to modulate lipid metabolism, such as enhancing cholesterol efflux via APOE or re-ducing neurotoxic ceramides, offer potential avenues for intervention. The review also highlights the roles of neuroinflammation and oxidative stress as mediators of metabolic dysfunction in AD, underscoring the need for multifaceted approaches that target both metabolic and inflammatory pathways. The emerging field of precision medicine offers opportunities to tailor interventions based on individual metabolic pro-files, potentially enhancing treatment efficacy. Despite the growing recognition of metabolic dysfunction in AD, translating these insights into effective therapies remains challenging due to the disease's com-plexity and heterogeneity. Future research must focus on elucidating the interplay between metabolic pathways and AD pathology, identifying reliable biomarkers, and designing targeted interventions. By addressing the metabolic underpinnings of AD, this review underscores the potential of metabolic repro-gramming as a novel and integrative therapeutic strategy to slow or prevent disease progression and im-prove patient outcomes.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗View full text ↗

Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief